LEADER 01057nam--2200349---450 001 990001407170203316 005 20210215104115.0 035 $a000140717 035 $aUSA01000140717 035 $a(ALEPH)000140717USA01 035 $a000140717 100 $a20040210d1969----km-y0itay0103----ba 101 0 $aita 102 $aIT 105 $aa|||||||001yy 200 1 $a<> momento buono$eil movimento garibaldino bellunese nella lotta di liberazione del Veneto$ecento pagine di documenti$fMario Bernardo$gintroduzione di Giovanni Falaschi 210 $aRoma$cIdeologie$d1969 215 $a275 p., [1], 25 carte di tav.$cill.$d22 cm 410 0$12001 454 1$12001 461 1$1001-------$12001 606 0 $aResistenza$yBelluno 676 $a940.54 700 1$aBERNARDO,$bMario$0469625 702 1$aFALASCHI,$bGiovanni 801 0$aIT$bsalbc$gISBD 912 $a990001407170203316 951 $aX.3.A. 389(III D 376)$b43193 L.M.$cIII D 959 $aBK 969 $aUMA 996 $aMomento buono$9216855 997 $aUNISA LEADER 04676nam 22007455 450 001 9910300354403321 005 20250729152212.0 010 $a3-319-08374-0 024 7 $a10.1007/978-3-319-08374-2 035 $a(CKB)3710000000269614 035 $a(EBL)1965469 035 $a(SSID)ssj0001372824 035 $a(PQKBManifestationID)11888504 035 $a(PQKBTitleCode)TC0001372824 035 $a(PQKBWorkID)11304647 035 $a(PQKB)11185381 035 $a(MiAaPQ)EBC1965469 035 $a(DE-He213)978-3-319-08374-2 035 $a(PPN)182093093 035 $a(EXLCZ)993710000000269614 100 $a20141029d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aUnderstanding Evidence-Based Rheumatology $eA Guide to Interpreting Criteria, Drugs, Trials, Registries, and Ethics /$fedited by Hasan Yazici, Yusuf Yazici, Emmanuel Lesaffre 205 $a1st ed. 2014. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2014. 215 $a1 online resource (285 pages) 300 $aDescription based upon print version of record. 311 0 $a3-319-08373-2 320 $aIncludes bibliographical references and index. 327 $a 1. Evidence in Rheumatology: How Does It Differ from Other Diseases?.- 2. A Review of Statistical Approaches for the Analysis of Data in Rheumatology.- 3. Disease Classification/Diagnosis Criteria -- 4. Biomarkers, Genetic Association and Genomic Studies.- 5. Outcome Measures in Rheumatoid Arthritis -- 6. Issues in Setting Up a Study and Data Collection -- 7. The Randomized Controlled Trial: Methodological Perspectives -- 8. Limitations of Traditional Randomized Controlled Clinical Trials in Rheumatology -- 9. Methodological Issues Relevant to Observational Studies, Registries and Administrative Health Databases in Rheumatology -- 10. Systematic Reviews and Meta-analyses in Rheumatology -- 11. Ethical Issues in Study Design and Reporting -- 12. Future Directions. 330 $aIt is imperative that health professionals caring for patients with rheumatic diseases understand how to correctly interpret evidence in their field, taking into account the merits and shortcomings of available data. Understanding Evidence-Based Rheumatology offers a practical assessment of criteria, drugs, trials, and registries and provides useful tools for successfully interpreting this data. The book introduces readers to basic analysis of trial design, statistics, and application of data through no-nonsense, easy-to-follow insights. Using numerous examples, chapters outline the difficulties physicians encounter when measuring disease activity in rheumatology, and offer strategies for systematically approaching these situations. Ethical issues in study design and reporting are examined, and the book closes with a summary of future directions for scientific and clinical studies in rheumatology. Understanding Evidence-Based Rheumatology is an invaluable resource for trainees, experienced clinicians, and scientists, preparing them with the necessary tools to correctly gather evidence and shed light on the difficult practice of rheumatology.  . 606 $aRheumatology 606 $aInternal medicine 606 $aEvidence-based medicine 606 $aRheumatic Diseases$3(DNLM)D012216 606 $aCollagen Diseases$3(DNLM)D003095 606 $aEvidence-Based Medicine$3(DNLM)D019317 606 $aRheumatology$3(DNLM)D012219 606 $aRheumatology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33170 606 $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002 606 $aMedicine/Public Health, general$3https://scigraph.springernature.com/ontologies/product-market-codes/H00007 615 0$aRheumatology. 615 0$aInternal medicine. 615 0$aEvidence-based medicine. 615 12$aRheumatic Diseases. 615 22$aCollagen Diseases. 615 22$aEvidence-Based Medicine. 615 22$aRheumatology. 615 14$aRheumatology. 615 24$aInternal Medicine. 615 24$aMedicine/Public Health, general. 676 $a610 676 $a616 676 $a616723 702 $aYazici$b Hasan$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aYaz?c?$b Yusuf$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aLesaffre$b Emmanuel$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300354403321 996 $aUnderstanding Evidence-Based Rheumatology$91521747 997 $aUNINA